1. Steinman L. Immunology of Relapse and Remission in Multiple Sclerosis. Annu Rev Immunol 2014; 32:257-81 [
DOI:10.1146/annurev-immunol-032713-120227] [
PMID]
2. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis Brains. Brain 2009;132(5):1175-89. [
DOI:10.1093/brain/awp070] [
PMID] [
PMCID]
3. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD. Neurological Disability Correlates with Spinal Cord Axonal Loss and Reduced N‐acetyl Aspartate in Chronic Multiple Sclerosis Patients. Ann Neurol 2000;48(6):893-901.
https://doi.org/10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B [
DOI:10.1002/1531-8249(200012)48:63.0.CO;2-B]
4. Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Brück W. Differentiation Block of Oligodendroglial Progenitor Cells as a Cause for Remyelination Failure in Chronic Multiple Sclerosis. Brain 2008;131(7):1749-58. [
DOI:10.1093/brain/awn096] [
PMID]
5. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple Sclerosis: Lessons from Neuropathology. Semin Neurol 1998;18(3):337-49. [
DOI:10.1055/s-2008-1040885] [
PMID]
6. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal Fluid and Plasma Biomarkers in Alzheimer Disease. Nat Rev Neurosci 2010;6(3):131-44. [
DOI:10.1038/nrneurol.2010.4]
7. Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau Cerebrospinal Fluid Biomarkers in HIV Infection. BMC Neurol 2009;9(1):63. [
DOI:10.1186/1471-2377-9-63] [
PMID] [
PMCID]
8. Sjögren M, Gisslén M, Vanmechelen E, Blennow K. Low Cerebrospinal Fluid β-amyloid 42 in Patients with Acute Bacterial Meningitis and Normalization after Treatment. Neurosci Lett 2001;314(1):33-6. [
DOI:10.1016/S0304-3940(01)02285-6]
9. Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased Levels of Soluble Amyloid β-protein Precursor and β-amyloid Protein in Cerebrospinal Fluid of Patients with Systemic Lupus Erythematosus. Arthritis Res Ther 2004;6(2):R129- R36. [
DOI:10.1186/ar1040] [
PMID] [
PMCID]
10. Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, Anckarsäter R, et al. Reduced Cerebrospinal Fluid BACE1 Activity in Multiple Sclerosis. Mult Scler J 2009;15(4):448-54. [
DOI:10.1177/1352458508100031] [
PMID]
11. Mattsson N, Bremell D, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, et al. Neuroinflammation in Lyme Neuroborreliosis Affects Amyloid Metabolism. BMC Neurol 2010;10(1):51. [
DOI:10.1186/1471-2377-10-51] [
PMID] [
PMCID]
12. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid Precursor Protein (APP) Expression in Multiple Sclerosis Lesions. Glia 1995;15(2):141-51. [
DOI:10.1002/glia.440150206] [
PMID]
13. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal Transection in the Lesions of Multiple Sclerosis. N Engl J Med 1998;338(5):278-85. [
DOI:10.1056/NEJM199801293380502] [
PMID]
14. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal Damage in Acute Multiple Sclerosis Lesions. Brain 1997;120(3):393-9. [
DOI:10.1093/brain/120.3.393] [
PMID]
15. Grant JL, Ghosn EEB, Axtell RC, Herges K, Kuipers HF, Woodling NS, et al. Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis. Sci Transl Med 2012;4(145):145ra05.
16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol 2011;69(2):292-302. [
DOI:10.1002/ana.22366] [
PMID] [
PMCID]
17. Ziemssen T. Multiple Sclerosis Beyond EDSS: Depression and Fatigue. J Neurol Sci 2009; 277 Suppl 1:S37-41. [
DOI:10.1016/S0022-510X(09)70011-5]
18. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, et al. Cerebrospinal Fluid Biomarkers of β-amyloid Metabolism in Multiple Sclerosis. Mult Scler J 2013;19(5):543-52. [
DOI:10.1177/1352458512460603] [
PMID]
19. Pietroboni AM, Schiano di Cola F, Scarioni M, Fenoglio C, Spanò B, Arighi A, et al. CSF β-amyloid as a Putative Biomarker of Disease Progression in Multiple Sclerosis. Mult Scler 2016;23(8):1085-91. [
DOI:10.1177/1352458516674566] [
PMID]
20. Mai W, Hu X, Lu Z, Peng F, Wang Y. Cerebrospinal Fluid Levels of Soluble Amyloid Precursor Protein and β-amyloid 42 in Patients with Multiple Sclerosis, Neuromyelitis Optica and Clinically Isolated Syndrome. J Int Med Res 2011;39(6):2402-13. [
DOI:10.1177/147323001103900641] [
PMID]
21. Mori F, Rossi S, Sancesario G, Codecà C, Mataluni G, Monteleone F, et al. Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis. Neuropsychopharmacology 2011;36(3):559-68. [
DOI:10.1038/npp.2010.187] [
PMID] [
PMCID]
22. Clarner T, Buschmann JP, Beyer C, Kipp M. Glial Amyloid Precursor Protein Expression Is Restricted to Astrocytes in an Experimental Toxic Model of Multiple Sclerosis. J Mol Neurosci 2011;43(3):268-74. [
DOI:10.1007/s12031-010-9419-9] [
PMID]
23. Yokote H, Yagi Y, Watanabe Y, Amino T, Kamata T, Mizusawa H. Serum Amyloid A Level Is Increased in Neuromyelitisoptica and Atypical Multiple Sclerosis with Smaller T2 Lesion Volume in Brain MRI. J Neuroimmunol 2013;259(1):92-5. [
DOI:10.1016/j.jneuroim.2013.03.004] [
PMID]
24. Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, Pozzilli C, et al. Serum Amyloid A Protein Is Elevated in Relapsing–remitting Multiple Sclerosis. J Neuroimmunol 1998;88(1):9-12. [
DOI:10.1016/S0165-5728(98)00037-X]
25. Schroder R, Nennesmo I, Linke RP. Amyloid in a Multiple Sclerosis Lesion Is Clearly of A Lambda Type. Acta Neuropathol 2000;100(6):709-11. [
DOI:10.1007/s004010000244] [
PMID]